Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

granulocyte

granulocyte is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 11
Pipeline programs 6
News articles 0
Drug details — granulocyte
Class
—
Route
—
Patents
11
Programs
6
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

granulocyte is an FDA-listed pharmaceutical active ingredient.

Key facts

INN granulocyte

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. G-SCF Phase 3 · First People's Hospital · Granulocyte Colony-stimulating Factor
  2. Granulocyte Colony-Stimulating Factor(G-CSF) Phase 3 · Chinese Academy of · Myelodysplastic Syndrome
  3. S2023-056-01 Phase 2 · Chinese Academy of · Acute Myeloid Leukemia
  4. S2023-413-01 Phase 2 · Chinese Academy of · Relapsed/Refractory Acute Myeloid Leukemia
  5. Granulocyte Colony-Stimulating Factor Phase 1 · United Therapeutics Europe · Biliary Atresia
  6. G-CSF (Granulocyte colony-stimulating factor) Unknown · First People's Hospital · Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization

Related patents

Browse patents

  1. US 11413274

    Methods and compositions associated with the granulocyte colony-stimulating factor receptor

    Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11085022

    Inflammation-targeted neutrophil granulocyte drug delivery system and use thereof

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11078264

    Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10813913

    Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10736875

    Methods and compositions associated with the granulocyte colony-stimulating factor receptor

    Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10420748

    Methods of treatment associated with the granulocyte colony-stimulating factor receptor

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10376495

    Small molecules that mimic or antagonize actions of granulocyte colony-stimulating-factor (G-CSF)

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10111859

    Methods and compositions associated with the granulocyte colony-stimulating factor receptor

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9962370

    Methods of treatment associated with the granulocyte colony-stimulating factor receptor

    Expires Mon May 03 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9492430

    Methods and compositions associated with the granulocyte colony-stimulating factor receptor

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9161969

    Protection against influenza infection by granulocyte-macrophage colony stimulating factor

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is granulocyte?

granulocyte is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.